Cited by 42Antifungal resistance and susceptibilityImmunodeficiency and Autoimmune DisordersFungal and yeast genetics research

Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium

Open access
Lupiañez, C. B., Canet, L. M., Carvalho, A., Alcazar-Fuoli, L., Springer, J., Lackner, M., Segura-Catena, J., Comino, A. +22 more·2016·Infection and Immunity

Abstract

Recent studies suggest that immune-modulating single-nucleotide polymorphisms (SNPs) influence the risk of developing cancer-related infections. Here, we evaluated whether 36 SNPs within 14 immune-related genes are associated with the risk of invasive aspergillosis (IA) and whether genotyping of these variants might improve disease risk prediction. We conducted a case-control association study of 781 immunocompromised patients, 149 of whom were diagnosed with IA. Association analysis showed that the IL4Rrs2107356 and IL8rs2227307 SNPs (using dbSNP numbering) were associated with an increased risk of IA (IL4Rrs2107356 odds ratio [OR], 1.92; 95% confidence interval [CI], 1.20 to 3.09;IL8rs2227307 OR, 1.73; 95% CI, 1.06 to 2.81), whereas the IL12Brs3212227 and IFN γ rs2069705 variants were significantly associated with a decreased risk of developing the infection (IL12Brs3212227 OR, 0.60; 95% CI, 0.38 to 0.96;IFN γ rs2069705 OR, 0.63; 95% CI, 0.41 to 0.97). An allogeneic hematopoietic stem cell transplantation (allo-HSCT)-stratified analysis revealed that the effect observed for the IL4Rrs2107356 and IFN γ rs2069705 SNPs was stronger in allo-HSCT (IL4Rrs2107356 OR, 5.63; 95% CI, 1.20 to 3.09;IFN γ rs2069705 OR, 0.24; 95% CI, 0.10 to 0.59) than in non-HSCT patients, suggesting that the presence of these SNPs renders patients more vulnerable to infection, especially under severe and prolonged immunosuppressive conditions. Importantly,in vitro studies revealed that carriers of the IFN γ rs2069705C allele showed a significantly increased macrophage-mediated neutralization of fungal conidia (P= 0.0003) and, under stimulation conditions, produced higher levels of gamma interferon (IFNγ) mRNA (P= 0.049) and IFNγ and tumor necrosis factor alpha (TNF-α) cytokines (P value for 96 h of treatment with lipopolysaccharide [PLPS-96 h], 0.057;P value for 96 h of treatment with phytohemagglutinin [PPHA-96 h], 0.036;PLPS+PHA-96 h= 0.030;PPHA-72 h= 0.045;PLPS+PHA-72 h= 0.018;PLPS-96 h= 0.058;PLPS+PHA-96 h= 0.0058). Finally, we also observed that the addition of SNPs significantly associated with IA to a model including clinical variables led to a substantial improvement in the discriminatory ability to predict disease (area under the concentration-time curve [AUC] of 0.659 versus AUC of 0.564;P−2 log likehood ratio test= 5.2 · 10−4 and P50.000 permutation test= 9.34 · 10−5). These findings suggest that the IFN γ rs2069705 SNP influences the risk of IA and that predictive models built with IFN γ,IL8,IL12p70, and VEGFA variants can used to predict disease risk and to implement risk-adapted prophylaxis or diagnostic strategies.

Integrity signals

Registry

Crossref · 10.1128/iai.01359-15

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Polymorphisms within the interferon-gamma gene and its receptor are associated with fungal disease risk, and auto-antibodies to IFN-gamma are associated with an increased rate of fungal infections.

    “Polymorphisms within the interferon-γ (INF-γ) gene [39] and its receptor have also been associated with fungal disease risk, and auto-antibodies to IFN-γ have similarly seen an increased rate of fungal infections and may be more frequent in some patient groups [40].”

    From Race and ethnicity: Risk factors for fungal infections? (2023) · cites this paper as [39]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lupiañez, C. B., Canet, L. M., Carvalho, A., Alcazar-Fuoli, L., Springer, J., Lackner, M., Segura-Catena, J., Comino, A., Olmedo, C., Ríos, R., Fernández-Montoya, A., Cuenca-Estrella, M., Solano, C., López-Nevot, M. Á., Cunha, C., Oliveira-Coelho, A., Villaescusa, T., Fianchi, L., Aguado, J. M., Pagano, L., López-Fernández, E., Potenza, L., Luppi, M., Lass-Flörl, C., Loeffler, J., Einsele, H., Vazquez, L., the PCRAGA Study Group, Jurado, M., & Sainz, J.
Affiliations
  • Universidad de Granada (ES)
  • University of Minho (PT)
  • Mycology Reference Laboratory, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
  • Universitätsklinikum Würzburg (DE)
  • Innsbruck Medical University (AT)
  • Hospital Universitario Virgen de las Nieves (ES)
  • Blood Transfusion Regional Centre and Sectorial Tissue Bank, Granada, Spain
  • Hospital Clínico Universitario de Valencia (ES)
  • Immunology Department, Virgen de las Nieves University Hospital, Granada, Spain
  • Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
  • Complejo Hospitalario de Salamanca (ES)
  • Università Cattolica del Sacro Cuore (IT)
  • Research Institute Hospital 12 de Octubre (ES)
  • Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain
  • University of Modena and Reggio Emilia (IT)
  • Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
  • Hematology Department, University Hospital of Salamanca, Salamanca, Spain
  • Genomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain
Venue
Infection and Immunity
Published
2016-03
Volume
84
Issue
3
Pages
643-657
ISSN
  • 0019-9567 (ISSN-L)
  • 1098-5522
OpenAlex
W2219758163
Cited by
42
References
96
Citations by year
2025: 3 · 2024: 2 · 2023: 4 · 2022: 9 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 6 · 2017: 4 · 2016: 3
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • Infection and Immunity (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
Funders
  • ERA-NET Pathogenomics (PIM2010EPA-00756)
  • Fondo de Investigaciones Sanitarias (PI12/02688)
  • The Collaborative Research Center/Transregio 124 FungiNet
  • Fundação para a Cincia e Tecnologia, Portugal, (SFRH/BPD/96176/2013)
  • Astellas Pharma
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
invasive aspergillosis, single nucleotide polymorphisms, interleukin-4 receptor, interleukin-8, IL12B, interferon-gamma, genetic susceptibility, immunocompromised patients, allogeneic hematopoietic stem cell transplantation, cancer-related infections, risk prediction, immunosuppression
MeSH terms
Adult, Aged, Alleles, Aspergillosis, Female, Genotype, Humans, Interferon-gamma, Male, Middle Aged, Case-Control Studies, Interleukin-8, Immunocompromised Host, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Interleukin-4 Receptor alpha Subunit, Interleukin-12 Subunit p40

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review